Our Expert Network

  1. Engineering Transient In Vivo CAR-T: Extending Expression, Expanding Access, And Rethinking Immune Reset 5/4/2026

    In this Q&A, Michael Lam, Ph.D., explores how circular RNA and targeted delivery extend transient CAR expression to enable deep B-cell depletion and controllable immune reset.

  2. Engineering Repeat-Dose RNA: Engineering Around Immune Recognition In Repeat-Dose RNA Therapeutics 4/30/2026

    Designing repeat-dose RNA means engineering around immune recognition — optimizing payloads, purity, and delivery early to sustain efficacy, tolerability, and durability across multiple administrations.

  3. Bridging The Manufacturing Chemistries Between Drug Research And Development For Morpholino Oligos 4/29/2026

    Standardizing Morpholino chemistry could streamline development and FDA pathways, improving consistency, scalability, and delivery performance across antisense therapeutics.

  4. From Supporting Component to Strategic Driver: The Evolving Role of gRNA in CRISPR Therapeutics 4/21/2026

    Guide RNA is evolving from a simple targeting reagent into a complex, engineered molecule shaped by expanding CRISPR modalities, increasing length and modification demands, and tighter integration with manufacturability, analytical control, and regulatory expectations.

  5. A Novel Co-Tethered Transcription Platform For High-Yield, High-Purity mRNA Synthesis 4/15/2026

    Co-tethered transcription boosts mRNA yield and purity by organizing transcription machinery, reducing dsRNA impurities, and streamlining production for scalable RNA therapeutics.

  6. A New Approach To RNA Synthesis And Purification: Rethinking A Persistent Bottleneck 4/14/2026

    Photocleavable supports enable light-triggered RNA release, reducing reliance on chromatography and streamlining synthesis, scalability, and purity for complex RNA therapeutics.

  7. Oligos, mRNA, Or Gene Editing: Where Should You Bet? 4/13/2026

    Investing in RNA and gene editing requires balancing risk, timing, and scale — understanding how oligos, mRNA, and CRISPR each drive value across a converging biotech landscape.

  8. A Smarter Switch: Reprogramming CIP Systems With Nanobodies Unlocks New Control Over Cell Signaling 4/10/2026

    Engineered nanobodies reprogram CIP systems, enabling precise, reversible control of protein interactions, signaling pathways, and gene expression without redesigning core chemistry.

  9. Can Making mRNA More "Rigid" Unlock The Next Leap In RNA Medicines? 4/9/2026

    Can stabilizing mRNA structure unlock better performance? New strategies aim to “rigidify” mRNA, improving translation, stability, and manufacturability while reducing variability across conditions.

  10. Rethinking The Oligonucleotide Backbone: A New Approach To RNA Therapeutic Design 4/7/2026

    Backbone engineering reframes RNA design, enabling programmable charge, uptake, and delivery — transforming oligonucleotides from fixed structures into tunable, multifunctional therapeutic systems.